# A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

> **NCT07307443** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhijie Wang** · enrollment: 28 (estimated)

## Conditions studied

- SMARCA4-Deficient Tumor
- Locally Advanced or Metastatic Lung Cancer

## Interventions

- **DRUG:** Anlotinib, nab-paclitaxel, carboplatin

## Key facts

- **NCT ID:** NCT07307443
- **Lead sponsor:** Zhijie Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07307443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07307443, "A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07307443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*